<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: EHA 2021&#124; Daratumumab plus lenalidomide and dexamethasone (D-Rd) shows overall survival benefit in elderly patients with transplant-ineligible newly diagnosed myeloma	</title>
	<atom:link href="https://www.mpeurope.org/eha-2021-daratumumab-plus-lenalidomide-and-dexamethasone-d-rd-shows-overall-survival-benefit-in-elderly-patients-with-transplant-ineligible-newly-diagnosed-myeloma/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.mpeurope.org/eha-2021-daratumumab-plus-lenalidomide-and-dexamethasone-d-rd-shows-overall-survival-benefit-in-elderly-patients-with-transplant-ineligible-newly-diagnosed-myeloma/</link>
	<description></description>
	<lastBuildDate>Mon, 14 Jun 2021 05:55:27 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.5</generator>
</channel>
</rss>
